# ET-01 in Subjects With Lateral Canthal Lines, LCL-209

> **NCT03912805** · PHASE2 · COMPLETED · sponsor: **Eirion Therapeutics Inc.** · enrollment: 38 (actual)

## Conditions studied

- Lateral Canthal Lines, LCL
- Crow's Feet

## Interventions

- **BIOLOGICAL:** botulinum toxin, Type A
- **BIOLOGICAL:** Vehicle

## Key facts

- **NCT ID:** NCT03912805
- **Lead sponsor:** Eirion Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-27
- **Primary completion:** 2019-05-06
- **Final completion:** 2019-10-04
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2022-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03912805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03912805, "ET-01 in Subjects With Lateral Canthal Lines, LCL-209". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT03912805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*